Show simple item record

dc.contributor.authorWalsh, David A
dc.date.accessioned2021-12-01T14:45:14Z
dc.date.available2021-12-01T14:45:14Z
dc.date.issued2015-06
dc.identifier.citationMercer, L. K. et al. (2015) ‘Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis’, Annals of the Rheumatic Diseases, 74(6), pp. 1087–1093en_US
dc.identifier.urihttp://hdl.handle.net/20.500.12904/14997
dc.description.abstractBackground: Patients with rheumatoid arthritis (RA) have an increased risk of certain solid cancers, in particular lung cancer, compared to the general population. Treatment with tumour necrosis factor (TNF) inhibitors (TNFi) may further enhance this risk. Objectives: To compare the risk of solid cancer in patients with RA treated with TNFi to that in patients treated with non-biologic (synthetic) disease modifying antirheumatic drugs (sDMARDs). Methods: Patients with a physician diagnosis of RA enrolled in the British Society for Rheumatology Biologics Register, a national prospective cohort study established in 2001 to monitor the long-term safety of TNFi, were followed via record linkage with the national cancer registries until first solid cancer, death, for 5 years, or until 2011. Rates of solid cancers in 11 767 patients without prior cancer who received TNFi were compared to those in 3249 patients without prior cancer treated with sDMARDs. Results: 427 solid cancers were reported in 52 549 patient-years follow-up for the TNFi group (81 (95% CI 74 to 89) per 10 000 patient-years) and 136 cancers were reported in 11 672 patient-years in the sDMARD cohort (117 (95% CI 98 to 138) per 10 000 patient-years). After adjusting for differences in baseline characteristics there was no difference in risk of solid cancer for TNFi compared to sDMARD treated patients: HR 0.83 (95% CI 0.64 to 1.07). There was no difference in the relative risk of cancer for any of the individual TNFi drugs. Conclusions: The addition of TNFi to sDMARD does not alter the risk of cancer in RA patients selected for TNFi in the UK.
dc.description.urihttps://ard.bmj.com/content/74/6/1087.longen_US
dc.publisherAnnals of the Rheumatic Diseasesen_US
dc.subjectAnti-TNFen_US
dc.subjectEpidemiologyen_US
dc.subjectRheumatoid arthritisen_US
dc.titleRisk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritisen_US
dc.typeArticleen_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US
rioxxterms.versionNAen_US
rioxxterms.versionofrecord10.1136/annrheumdis-2013-204851en_US
rioxxterms.typeJournal Article/Reviewen_US
refterms.dateFOA2021-12-01T14:45:15Z
refterms.panelUnspecifieden_US
refterms.dateFirstOnline2014-03
html.description.abstractBackground: Patients with rheumatoid arthritis (RA) have an increased risk of certain solid cancers, in particular lung cancer, compared to the general population. Treatment with tumour necrosis factor (TNF) inhibitors (TNFi) may further enhance this risk. Objectives: To compare the risk of solid cancer in patients with RA treated with TNFi to that in patients treated with non-biologic (synthetic) disease modifying antirheumatic drugs (sDMARDs). Methods: Patients with a physician diagnosis of RA enrolled in the British Society for Rheumatology Biologics Register, a national prospective cohort study established in 2001 to monitor the long-term safety of TNFi, were followed via record linkage with the national cancer registries until first solid cancer, death, for 5 years, or until 2011. Rates of solid cancers in 11 767 patients without prior cancer who received TNFi were compared to those in 3249 patients without prior cancer treated with sDMARDs. Results: 427 solid cancers were reported in 52 549 patient-years follow-up for the TNFi group (81 (95% CI 74 to 89) per 10 000 patient-years) and 136 cancers were reported in 11 672 patient-years in the sDMARD cohort (117 (95% CI 98 to 138) per 10 000 patient-years). After adjusting for differences in baseline characteristics there was no difference in risk of solid cancer for TNFi compared to sDMARD treated patients: HR 0.83 (95% CI 0.64 to 1.07). There was no difference in the relative risk of cancer for any of the individual TNFi drugs. Conclusions: The addition of TNFi to sDMARD does not alter the risk of cancer in RA patients selected for TNFi in the UK.en_US
rioxxterms.funder.project94a427429a5bcfef7dd04c33360d80cden_US


Files in this item

Thumbnail
Name:
Risk of solid cancer in patients ...
Size:
663.1Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record